Abizaid Alexandre, Ribamar Costa J
Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
Hospital do Coração - Associação do Sanatorio Sírio, São Paulo, Brazil.
Catheter Cardiovasc Interv. 2016 Nov;88(S1):54-59. doi: 10.1002/ccd.26813.
First-generation bioresorbable scaffolds (BRS), represented by the three marked-approved devices (Absorb BVS 1.1, DESolve NX, and DREAMS) have demonstrated, in low to moderate angiographic scenarios, similar efficacy to current generation metallic drug-eluting stents. However, a trend toward more device thrombosis have been observed, especially when the scaffolds are used in off-label situations. Among the main shortcomings of this novel technology, we highlight: (1) Increased strut thickness (≥150 μm) and crossing profile; (2) low resistance to overexpansion; (3) lack of radiopacity, and; (4) special storage requirements. In order to overcome these limitations and improve their acute performance and midterm safety, a dozen of novel BRS are currently under research, in different stages of development. In the present review, we address three of these new technologies, pointing out their innovative features and initial clinical results. © 2016 Wiley Periodicals, Inc.
以三种已获批的标志性器械（Absorb BVS 1.1、DESolve NX和DREAMS）为代表的第一代生物可吸收支架（BRS），在低至中度血管造影情况下，已证明其疗效与当代金属药物洗脱支架相似。然而，已观察到器械血栓形成增加的趋势，尤其是当支架用于非标签情况时。在这项新技术的主要缺点中，我们着重指出：（1）支架厚度增加（≥150μm）和通过轮廓；（2）对过度扩张的抵抗力低；（3）缺乏射线不透性，以及；（4）特殊的储存要求。为了克服这些限制并改善其急性性能和中期安全性，目前有十几种新型BRS正处于不同研发阶段的研究中。在本综述中，我们探讨其中三种新技术，指出它们的创新特性和初步临床结果。©2016威利期刊公司。
